Abstract
AbstractBiomarkers of neurodegenerative diseases (ND) detected in cerebrospinal fluid (CSF) are numerous but only a few of them are validated and informative for clinicians. Only two biomarkers are currently included in routine clinical parameters: tau protein (and its phosphorylated forms [p-tau] in particular at position 181) and amyloid peptides (Aß40, Aß42). Analytical methods allowing the quantification of these biomarkers have evolved considerably in recent years, ensuring a high sensitivity of their detection even in the early stages of the disease where the alterations of these biomarkers are still very weak and therefore difficult to quantify. Various candidate biomarkers are also being studied (markers of neuronal suffering, reaction, inflammation, etc.), in particular neurofilament light chains (NfL), which seems to be particularly promising for the diagnosis and prognosis of various ND. The aim of this article is to present the informative value of current ND CSF diagnostic biomarkers (including t-tau, p-tau, Abß0, Aß42) and NfL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
